- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07557914
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
A Multicenter, Prospective, Single-arm Clinical Study Evaluating the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Chemotherapy Infusion (HAIC), Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable Hepatocellular Carcinoma and Diabetes
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Hongbin Zou
- Número de teléfono: +8618040026871
- Correo electrónico: hongbinzou300@gmail.com
Ubicaciones de estudio
-
-
Liaoning
-
Shenyang, Liaoning, Porcelana, 110000
- The First Hospital of China Medical University
-
Contacto:
- Haibo Shao
- Número de teléfono: +8613840150051
- Correo electrónico: haiboshao@aliyun.com
-
Contacto:
- Tao Han
- Número de teléfono: 8617790995045
- Correo electrónico: than1984@sina.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Diabetes mellitus combined with unresectable advanced HCC (BCLC stage C);
- Patients who have the need for treatment, prevention and improvement of diabetic neuropathy;
- Liver function at Child-Pugh grade A or B (≤ 7 points), ECOG PS 0-1;
- Age 18-80 years old. Confirmed as unrectable HCC through pathological or imaging diagnosis;
Exclusion Criteria:
- Severe liver dysfunction: Child-Pugh C grade (≥ 8 points) or active hepatic encephalopathy Illness;
- Extensive extrahepatic metastases (e.g., lung, bone, or peritoneum metastases);
- Severe cardiovascular diseases: Uncontrolled heart failure, recent myocardial infarction;
- Renal failure: Creatinine clearance rate < 30 mL/min;
- Thrombocytopenia (less than 50×10⁹/L) or coagulation dysfunction (INR greater than 1.5);
- Active infection (such as uncontrolled hepatitis B virus replication with HBV-DNA > 2000 IU/mL);
- ECOG PS ≥ 2 or extremely poor overall condition;
- Diabetic patients with acute ketoacidosis or during the period of severe infection;
- Pregnant and lactating women;
- Known history of other malignancy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Epalrestat plus HAIC, donafenib and tislelizumab
Epalrestat 50mg tid, donafenib 0.2g bid, tislelizumab 200mg per 21days, HAIC (FOLFOX or RALOX) per 21days |
For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day. donafenib 0.2g BID, tislelizumab 200mg/21days Include FOLFOX and RALOX.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
12-month Event-free survival (EFS) Rate
Periodo de tiempo: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
The proportion of patients who have remained event-free from the start of treatment until the 12-month time point.(Predefined events include: progression of disease, death for any reason, terminate the treatment due to intolerable AEs.) |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Event-free survival (EFS)
Periodo de tiempo: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Defined as the time from treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs). |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
|
Overall survival (OS)
Periodo de tiempo: Up to approximately 2 years
|
The OS is defined as the time from the enrollment to death due to any cause. |
Up to approximately 2 years
|
|
Progression free survival(PFS) (Overall)
Periodo de tiempo: From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first. |
From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of intra-hepatic lesions
Periodo de tiempo: From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of extra-hepatic lesions
Periodo de tiempo: From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Objective response rate(ORR) per RESCIST 1.1
Periodo de tiempo: Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1. |
Up to approximately 2 years
|
|
ORR per mRECIST
Periodo de tiempo: Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST. |
Up to approximately 2 years
|
|
PVTT response rate per mRECIST
Periodo de tiempo: Up to approximately 2 years
|
The PVTT response rate is defined as the proportion of patients with a documented CR or PR of PVTT. According to the Vp classification: CR: PVTT disappears or the portal vein becomes completely unobstructed. PR: Decrease in VP classification. SD: Without PR and PD. PD: Increase in VP classification. |
Up to approximately 2 years
|
|
Disease control rate(DCR) per RESCIST 1.1
Periodo de tiempo: Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per RECIST 1.1. |
Up to approximately 2 years
|
|
DCR per mRECIST
Periodo de tiempo: Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per mRECIST. |
Up to approximately 2 years
|
|
Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
Periodo de tiempo: Up to approximately 2 years
|
The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0. |
Up to approximately 2 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Haibo Shao, First Hospital of China Medical University
- Investigador principal: Tao Han, First Hospital of China Medical University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias por sitio
- Neoplasias
- Enfermedades metabólicas
- Neoplasias por tipo histológico
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Trastornos del metabolismo de la glucosa
- Enfermedades del HIGADO
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias Hepaticas
- Carcinoma
- Enfermedades Nutricionales y Metabólicas
- Carcinoma Hepatocelular
- Diabetes mellitus
- tislelizumab
- donafenib
- Epalrestat
Otros números de identificación del estudio
- kelunshen【2025】2025-861-2
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Consent and privacy: Participants usually only agreed to data use in the original study. Sharing IPD may violate that agreement. And we want to protect our academic credit and avoid misuse of the data.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .